Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways

Current Opinion in Pharmacology

Volumn 7, Issue 3, 2007, Pages 339-343

  Malemud, Charles J ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 (4 FLUOROPHENYL) 4 (1 PHENYLETHYL 1,2,3,6 TETRAHYDROPYRIDIN 4 YL) 3 (PYRIDINE 4 YL) 1H PYRROLE; 4 PHENYL 5 PYRIDYL 1,3 THIAZOLE DERIVATIVE; 5 AMINO N PHENYL 1H PYRAZOL 4 YL 3 PHENYLMETHANONE DERIVATIVE; [3 [4 (1,4 DIAZPAN 1 YL) 6 [(6,6 DIMETHYLBICYCLO[3.1.1]HEPAN 2 1)METHANOAMINO] 1,3,5 TRIAZIN 2 YLAMINO] 4 METHYLBENZAMIDE]; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; AS 601245; BENZIMIDAZOLE DERIVATIVE; CELECOXIB; CEP 11004; CEP 1347; INDOLE 5 CARBOXAMIDE; LIGUSTILIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NATURAL PRODUCT; NEXAVIR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PS 200981; PYRAZOLE DERIVATIVE; R 130823; RESVERATROL; RO 3201195; SD 282; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TAK 715; TANGERETIN; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; ARTHRITIS; CANCER; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; DRUG SYNTHESIS; ENZYME REGULATION; HUMAN; IN VITRO STUDY; INFLAMMATORY DISEASE; LUNG DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

4-BUTYROLACTONE; ANIMALS; FLAVONES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; STILBENES;

EID: 34248331345     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.11.012     Document Type: Review

References (45)

1. Malemud C.J. Small molecular weight inhibitors of stress- activated and mitogen-activated protein kinases. Mini Rev Med Chem 6 (2006) 689-698. This review chronicled the development, structure, mechanism of action and biological activities of SMIs of SAP/MAPKs.
2. Malemud CJ: MAP kinases. In OA, Inflammation and Degradation: A Continuum. Edited by Buckwalter J, Lotz M, Stoltz J-F. IOS Press; 2007, in press.
3. -/- mice, this study showed that the JNK2 isoform is highly involved in metabolic syndrome, but JNK2 function is not as critical when JNK1 is fully expressed because of cross-talk between JNK isoforms.
4. Dong Z., and Bode A.M. Dialogue between ERKs and JNKs: friendly or antagonistic?. Mol Interv 3 (2003) 306-308
5. McDermott E.P., and O'Neill L.A.J. Ras participates in the activation of p38 MAPK by interleukin-1 by associating with IRAK, IRAK2, TRAF6 and TAK-1. J Biol Chem 277 (2002) 7808-7815
6. Meyer L.H., and Pap T. MAPK signalling in rheumatoid arthritis destruction: can we unravel the puzzle?. Arthritis Res Ther 7 (2005) 177-178. This review focused on recent data indicating that, in addition to JNK and ERK, stable activation of p38 kinase contributes to destructive arthritis in human TNF-α transgenic mice.
7. Kim A.L., Zhu Y., Zhu H., Han L., Kopelovich L., Bickers D.R., and Athar M. Resveratrol inhibits proliferation of human epidermoid carcinoma A431 cells by modulating MEK1 and AP-1 signalling pathways. Exp Dermatol 15 (2006) 538-546
8. Chen K.H., Weng M.S., and Lin J.K. Tangeretin suppresses IL-1β-induced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK and AKT activation in human lung carcinoma cells. Biochem Pharmacol 73 (2007) 215-227
9. Van Slambrouck S., Parmar V.S., Sharma S.K., De Bondt B., Fore F., Coopman P., Vanhoecke B.W., Boterberg T., Depypere H.T., Leclercq G., et al. Tangeretin inhibits extracellular-signal-regulated-kinase (ERK) phosphorylation. FEBS Lett 579 (2005) 1665-1669
10. Wang X., Li F., Zhang H., Geng Y., Yuan J., and Jiang T. Preparative isolation and purification of polymethoxylated flavones from Tangerine peel using high-speed counter-current chromatography. J Chromatogr A 1090 (2005) 188-192
11. Lu Q., Qiu T.-Q., and Yang H. Ligustilide inhibits vascular smooth muscle cells proliferation. Eur J Pharmacol 542 (2006) 136-140
12. Kuan C.-Y., and Burke R.E. Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Curr Drug Targets CNS Neurol Disord 4 (2005) 63-67
13. Wang L.H., Besirli C.G., and Johnson Jr. E.M. Mixed lineage kinases: a target for the prevention of neurodegeneration. Annu Rev Pharmacol Toxicol 44 (2004) 451-474
14. Ciallella J.R., Saporito M., Lund S., Leist M., Hasseldam H., McGann N., Smith C.S., Bozyczko-Coyne D., and Flood D.G. CEP-11004, an inhibitor of the SAPK/JNK pathway, reduces TNF-α release from lipopolysaccharide-treated cells and mice. Eur J Pharmacol 515 (2005) 179-187
15. Dominguez C., Powers D.A., and Tamayo N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel 8 (2005) 421-430
16. Lee M.R., and Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38α protein. Curr Med Chem 12 (2005) 2979-2994
17. Tamayo N., Liao L., Goldberg M., Powers D., Tudor Y.-Y., Yu V., Wong L.M., Henkle B., Middleton S., Syed R., et al. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase. Bioorg Med Chem Lett 15 (2005) 2409-2413
18. Korb A., Tohidast-Akrad M., Cetin E., Axmann R., Smolen J., and Schett G. Differential tissue expression and activation of p38 MAPK α, β, γ, δ isoforms in rheumatoid arthritis. Arthritis Rheum 54 (2006) 2745-2756. Using human synovial tissue biopsies combined with immunoblotting, immunoprecipitation and immunohistochemistry techniques, the authors revealed that the most frequent p38 kinase isoforms in inflamed rheumatoid arthritis joints are p38α and p38γ.
19. Medicherla S., Ma J.Y., Mangadu R., Jiang Y., Zhao J.J., Almirez R., Kerr I., Stebbins E.G., O'Young G., Kapoun A.M., et al. A selective p38α mitogen- activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J Pharmacol Exp Ther 318 (2006) 132-141
20. Kirkwood K.L., Li F., Rogers J.E., Otremba J., Coatney D.D., Kreider J.M., D'Silva N.J., Chakravarty S., Dugar S., Linda H.S., et al. A p38α selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss. J Pharmacol Exp Ther 320 (2007) 56-63. This study showed that the p38α-selective SMI SD-282 blocked arthritis progression in murine collagen-induced arthritis, even in those arthritic mice with existing bone and cartilage degeneration.
21. Smith S.J., Fenwick P.S., Nicholson A.G., Kirschenbaum F., Finney-Haywood T.K., Higgins L.S., Giembycz M.A., Barnes P.J., and Donnelly L.E. Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 149 (2006) 393-404
22. Li Z., Ma J.Y., Kerr I., Chakravarty S., Dugar S., Schreiner G., and Protter A.A. Selective inhibition of p38α MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury. Am J Physiol Heart Circ Physiol 291 (2006) H1972-H1977
23. Lin T.H., Metzger A., Diller D.J., Desai M., Henderson I., Ahmed G., Kimble E.F., Quadros E., and Webb M.L. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors. J Pharmacol Exp Ther 318 (2006) 495-502
24. De Dios A., Shih C., Lopez de Uralde B., Sanchez C., del Prado M., Martin Calbrejas L.M., Pleite S., Blanco-Urgoiti J., Lorite M.J., Nevill Jr. C.R., et al. Design of potent and selective 2-aminobenzimidazole-based p38α MAP kinase inhibitors with excellent in vivo efficacy. J Med Chem 48 (2005) 2270-2273
25. Goldstein D.M., Alfredson T., Bertrand J., Browner M.F., Clifford K., Dalrymple S.A., Dunn J., Freire-Moar J., Harris S., Labadie S.S., et al. Discovery of S-[5-amino-1-(4-flurophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy) phenyl] methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. J Med Chem 49 (2006) 1562-1575
26. 50 = 22 nM), reduced hind paw swelling in rat adjuvant and murine collagen-induced arthritis. R-130823 also ameliorated hyperalgesia in adjuvant arthritis, with rapid onset and in association with COX-2 inhibition.
27. Miwatashi S., Arikawa Y., Kotani E., Miyamoto M., Naruo K., Kimura H., Tanaka T., Asahi S., and Ohkawa S. Novel inhibitor of p38 MAP kinase an an anti-TNF-α drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl] benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J Med Chem 48 (2005) 5966-5979
28. Sharrocks A.D. Cell cycle: sustained ERK signaling represses the inhibitors. Curr Biol 16 (2006) R540-R542
29. Nishimoto S., and Nishida E. MAPK signalling: ERK5 versus ERK 1/2. EMBO Rep 7 (2006) 782-786
30. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 6 (2005) 827-837
31. Kohno M., and Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med 38 (2006) 200-211. This review focused on assessing the biological potency of BAY 43-9006, PD184352, PD325901 and ARRY-142886 as Raf and MEK-1/2 inhibitors. The paper also discussed their future use as anti-cancer agents in combination with traditional anti-cancer therapies (i.e. cytotoxic agents).
32. Staehler M., Rohrmann K., Haseke N., Stief C.G., and Siebels M. Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets 6 (2005) 835-846
33. Sosman J.A., and Puzanov I. Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res 12 (2006) 2376s-2383s
34. Wilhelm S.M., Carter C., Tang L.-Y., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
35. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., and Fagin J.A. High prevalence of BRAF mutations in thyroid cancer. Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63 (2003) 1454-1457
36. V599EB-RAF is an oncogene in melanocytes. Cancer Res 64 (2004) 2338-2342
37. i = 300 nM in vitro) and anti-cancer agents will be highly dependent upon the level of MEK activity in B-Raf-positive tumors, which suggested a rational approach to the therapy of genetically defined tumors.
38. Schreck R., and Rapp U.R. Raf kinases: oncogenes and drug discovery. Int J Cancer 119 (2006) 2261-2271
39. ®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407 (2005) 597-612
40. Malemud C.J. Growth hormone, FGF and VEGF: involvement in rheumatoid arthritis. Clin Chim Acta 375 (2007) 10-19
41. Hahn O., and Stadler W. Sorafenib. Curr Opin Oncol 18 (2006) 615-621
42. Ohren J.F., Chen H., Pavlovsky A., Whitehead C., Zhang E., Kuffa P., Yan C., McConnell P., Spessard C., Banotai C., et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11 (2004) 1192-1197
43. Delaney A.M., Printen J.A., Chen H., Fauman E.B., and Dudley D.T. Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD184352. Mol Cell Biol 22 (2002) 7593-7602
44. Brown AP, Carlson TC, Loi CM, Graziano MJ: Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901 in the rat following oral and intravenous administration. Cancer Chemother Pharmacol 2006, in press.
45. Thompson N., and Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5 (2005) 350-356. This review focused on the use of BAY 43-9006 and PD0325901, which are progressing through the late stages of clinical development, for use as anti-cancer agents.